Versatile, highly motivated, creative CMC-Strategist in multi-disciplinary research including analytical development of multiple therapeutic modalities including Mabs, vaccine, peptide conjugates and LVV based CAR-T cell therapies. Innovative problem solver with a diverse range of academic and industrial research experience with special focus on oncology, biochemistry, molecular and cellular biology. Proven excellence in collaborative projects as a leader and team player along with great organizational, and time management skills. Excellent communicator, enthusiastic instructor, and capable performer in a fast paced, result oriented GMP environment. Specialization:Proficient in method development, characterization, assay qualification, validation, analytical method transfers from early to late phase large molecule in compliance with established SOPs, procedures and regulatory requirements. CMC representative for Mabs, Lenti-viral based CAR-T cell therapies for effectively managing timelines and multiple projects from early to late stage to commercial and post commercial, contributing to project team and collaborating with colleagues on a global level. Leading analytical strategy for LVV based CAR-T cell therapies for ABECMA including LCM. Analytical minded scientist with a strong background in understanding FDA, and other regulatory CMC requirements through all phases of development, and life-cycle of drug products. Written several manuscripts and published in peer reviewed journals. Mentored junior colleagues and successfully trained graduate students.